Buy Back and Cancellation of Deferred Shares

RNS Number : 0383D

RUA Life Sciences PLC

24 June 2021

 

24 June 2021

RUA Life Sciences plc

("RUA" or the "Company")

Buy Back and Cancellation of Deferred Shares

Further to its announcement released on 23 June 2021, RUA Life Sciences plc (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon^TM, a long-term implantable biostable polymer, is pleased to announce that the Company has completed the Buy Back of all of its Deferred Shares, details of which were set out in the Circular sent to Shareholders dated 4 June 2021.  All of the Deferred Shares acquired have been cancelled.  Following the repurchase and cancellation of the Deferred Shares, there are no Deferred Shares in issue and the New Articles have been adopted. 

The Company's issued share capital following completion of the Buy Back of all of its Deferred Shares comprises 22,184,798 Ordinary Shares of which none are held in treasury.  The above figure of 22,184,798 may be used by Shareholders as the denomination for the calculations by which they will determine if they are required to notify their interest or a change in their interest in the voting rights in the Company under the FCA's Disclosure Guidance and Transparency Rules. 

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Circular sent to Shareholders dated 4 June 2021.

For more information please contact:

RUA Life Sciences plc

Bill Brown, Chairman  Tel: [phone]

David Richmond, CEO  Tel: [phone]

Shore Capital (Nomad and Joint Broker) 

Tom Griffiths/David Coaten  Tel: [phone]

Cenkos Securities plc (Joint Broker)  Tel: [phone]

Russell Cook/Max Gould (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon™, a long-term implantable polyurethane.

Whether it is licensing Elast-Eon™, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

RUA Medical   :	End-to-end contract designer and manufacturer of medical devices and implantable fabric specialist.
RUA Biomaterials:	Licensor of Elast-Eon™ polymers to the medical device industry.
RUA Vascular:	Commercialisation of large bore polymer sealed grafts and soft tissue patches.
RUA Structural Heart:	Development of polymeric leaflet systems for heart valves.

 

END

 

 

POSUSVARAKUNUAR